

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8155911

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
XIAOMING CHEN	05/04/2022
SHAOWEI ONG	05/05/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ANTARES PHARMA, INC.
<b>Street Address:</b>	100 CHARLES EWING BLVD.
<b>Internal Address:</b>	SUITE 300
<b>City:</b>	EWING
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08628
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	18056997
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(215)963-5001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2159634816
<b>Email:</b>	collins.mba-jonas@morganlewis.com
<b>Correspondent Name:</b>	JOHN L. HEMMER
<b>Address Line 1:</b>	MORGAN, LEWIS & BOCKIUS LLP
<b>Address Line 2:</b>	1701 MARKET STREET
<b>Address Line 4:</b>	PHILADELPHIA, PENNSYLVANIA 19103-2921
<b>ATTORNEY DOCKET NUMBER:</b>	063995-5083-US01
<b>NAME OF SUBMITTER:</b>	COLLINS N. MBA-JONAS, III
<b>SIGNATURE:</b>	/Collins N. Mba-Jonas, III/
<b>DATE SIGNED:</b>	09/08/2023
<b>Total Attachments: 2</b>	
source=Executed Assignment#page1.tif	
source=Executed Assignment#page2.tif	

**ASSIGNMENT**

**WHEREAS, WE, Xiaoming CHEN** with a post office address of 620 Boulevard, Westfield, NJ 07960, U.S.; and **Shaowei ONG** with a post office address of 1 Regents CT, Belle Mead, NJ 08502, U.S., hereinafter generally referred to as **ASSIGNORS** have invented a certain new and useful invention entitled:

**"AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL"**

that are described in U.S. Provisional Patent Application No. **63/081,164** filed **September 21, 2020**; U.S. Patent Application No. **17/494,340** filed **October 5, 2021**; and International Patent Application No. **PCT/US2021/051349** filed **September 21, 2021**, hereinafter referred to as the "Inventions" naming the above **ASSIGNORS** as inventors.

**WHEREAS, ANTARES PHARMA, INC.**, a corporation having a place of business at 100 Charles Ewing Blvd., Suite 300, Ewing, NJ 08628 hereinafter generally referred to as "ASSIGNEE," is desirous of acquiring and/or confirming the acquisition of the Inventions.

**NOW, THEREFORE**, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound hereby, I, **ASSIGNORS**, have assigned and/or by these presents do sell, assign, transfer and convey unto **ASSIGNEE**, the whole and entire right, title and interest in and to:

all Inventions;

the above patent applications and any and all United States and foreign patent applications disclosing one or more of the Inventions including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, requests for continued examinations, utility models, PCT applications and designs and any other related United States and foreign applications and equivalents thereof ("Applications"), along with the right to claim priority to the Applications under any treaty relating thereto;

all United States and foreign patents, utility models, inventor's certificates and designs and all equivalents thereof which may be granted for the Inventions or Applications, including extensions, renewals, reissues and reexamination certificates thereof ("Patents"); and

all rights to sue for and collect damages resulting from past, present and future infringement of all Patents.


The Inventions, Applications and Patents to be held and enjoyed by ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's legal representatives and assigns to the full end of the term or terms of said granted or to be granted Patents, as fully and entirely as the same would have been held by ASSIGNORS had this assignment and sale not been made; and for the aforesaid consideration ASSIGNORS hereby covenant, agree and undertake to execute, whenever requested by the above-named ASSIGNEE, all patent applications, assignments, lawful oaths and any other papers which ASSIGNEE may deem necessary or desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Inventions, Applications and Patents hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNORS.

It is agreed that ASSIGNORS shall be legally bound, upon request and at the expense of ASSIGNEE or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Inventions, and to testify in any legal proceeding relating thereto.


Each ASSIGNOR hereby represents and warrants that he/she has full right, power and authority to assign their entire right, title, and interest in the Patents, Applications, and Inventions, and to consummate the assignment contemplated herein. Each ASSIGNOR also represents and warrants that he/she has full right, power, and authority to enter into, execute, and deliver this Assignment, the execution and delivery of which have been duly authorized by all necessary action on the part of ASSIGNORS, and no other authorization or proceedings on the part of ASSIGNORS are necessary to authorize this Assignment. This Assignment has been duly executed and delivered and constitutes a valid, binding and enforceable assignment of the entire right, title, and interest in the Patents and Applications, and Inventions disclosed therein.

ASSIGNORS hereby warrant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.


04 May 2022  
Date

  
Xiaoming CHEN

5/5/2022  
Date

  
Shaowei ONG

3 MAY 2022  
Date

  
ANTARES PHARMA, INC.

NAME: Peter L. Sadowski, Ph.D.

TITLE: Senior Vice President, Technology Portfolio & Intellectual Property